
    
      The subjects enrolled in this study are healthy volunteers, divided into single dose groups
      and multiple doses groups with dose escalation.The study is designed to assign the subjects
      to five single-dose groups from low to high (0.0005%, 0.001%, 0.002%, 0.004% and 0.008%), and
      three multiple-dose groups (0.002%, 0.004% and 0.008%), with both male and female subjects in
      each group. This clinical trial is a double-blind design.
    
  